^
    Apply
    A Study of LY2784544 in Participants With Myeloproliferative Neoplasms (NCT01594723)
    Phase 2
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    03/21/2024
    Initiation :
    05/22/2012
    Primary completion :
    03/20/2015
    Completion :
    12/01/2024
    JAK2
    |
    JAK2 V617F • JAK2 mutation
    |
    gandotinib (LY 2784544)
    A Study in Myeloproliferative Disorders (NCT01134120)
    Phase 1
    Eli Lilly and Company
    Completed
    Last update posted :
    04/17/2018
    Initiation :
    04/01/2010
    Primary completion :
    04/01/2014
    Completion :
    02/22/2018
    JAK2
    |
    JAK2 V617F • JAK2 mutation
    |
    gandotinib (LY 2784544)